aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Spruce Biosciences is a biotechnology company dedicated to developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical needs. The company's core mission is to transform the lives of patients suffering from these conditions. Spruce's primary product candidate, tildacerfont, is a CRF receptor antagonist currently in late-stage clinical trials for treating adult patients with classic congenital adrenal hyperplasia (CAH).
Spruce Biosciences has made significant strides in the field of endocrinology and orphan drug development, focusing on innovative solutions for rare diseases. The company's commitment to addressing critical gaps in treatment options has positioned it as a key player in the biotech industry, particularly in the United States.
Operating Status
Active
Ownership Type(s)
Public, Venture Capital
Main Product(s)
Orphan Drugs
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Spruce Biosciences founded?
Spruce Biosciences was founded in 2014.
Where is Spruce Biosciences's headquarters located?
Spruce Biosciences's headquarters is located in San Francisco, CA, US.
When was Spruce Biosciences's last funding round?
Spruce Biosciences's most recent funding round was for $53.6M (USD) in February 2023.
How many employees does Spruce Biosciences have?
Spruce Biosciences has 47 employees as of Feb 6, 2024.
How much has Spruce Biosciences raised to-date?
As of July 05, 2023, Spruce Biosciences has raised a total of $161.6M (USD) since Feb 9, 2023.
Add Comparison
Total Raised to Date
$161.6M
USD
Last Update Feb 9, 2023
Last Deal Details
$53.6M
USD
Feb 9, 2023
Post Ipo Equity
Total Employees Over Time
47
As of Feb 2024
Spruce Biosciences Address
548 Market Street
San Francisco,
California
94104
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts